Auspex Pharmaceuticals major shareholder Ventures Vii Lp Cmea Sells 22,700 Shares (ASPX)
Auspex Pharmaceuticals (NASDAQ:ASPX) major shareholder Ventures Vii Lp Cmea sold 22,700 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $23.08, for a total value of $523,916.00. Following the completion of the transaction, the insider now directly owns 3,700,396 shares of the company’s stock, valued at approximately $85,405,140. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Auspex Pharmaceuticals (NASDAQ:ASPX) traded up 2.96% on Thursday, hitting $24.01. The stock had a trading volume of 142,455 shares. Auspex Pharmaceuticals has a 52 week low of $13.25 and a 52 week high of $35.78. The stock has a 50-day moving average of $20.20 and a 200-day moving average of $22.94. The company’s market cap is $550.8 million.
Auspex Pharmaceuticals (NASDAQ:ASPX) last announced its earnings results on Thursday, August 7th. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.33) by $0.12. On average, analysts predict that Auspex Pharmaceuticals will post $-2.03 earnings per share for the current fiscal year.
A number of research firms have recently commented on ASPX. Analysts at Stifel Nicolaus raised their price target on shares of Auspex Pharmaceuticals from $39.00 to $40.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. Analysts at Robert W. Baird raised their price target on shares of Auspex Pharmaceuticals from $34.00 to $42.00 in a research note on Friday, July 11th. They now have an “outperform” rating on the stock.
Auspex Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.